Half yearly and year to date results of the Company for the half year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
EP Biocomposites Limited submitted its audited half-yearly results for the period ended March 31, 2025 at a board meeting held on May 23, 2025. For the half year ended March 31, 2025, revenue from operations surged to ₹760.13 lakhs from ₹440.49 lakhs in the previous corresponding half year (around 72% growth), while profit after tax jumped to ₹82.53 lakhs from ₹20.55 lakhs (roughly fourfold increase). For the full financial year FY25, revenue grew modestly to ₹1,200.62 lakhs from ₹1,143.92 lakhs, but profit after tax dipped slightly to ₹103.08 lakhs from ₹114.97 lakhs, and EPS fell to ₹6.13 from ₹6.84. Statutory auditor S.P. Bhandare & Associates issued an unqualified opinion, stating the results give a true and fair view, with no going concern or emphasis of matter flagged. The company confirmed full utilization of its ₹580.04 lakh net IPO proceeds toward lease deposits, loan repayment, working capital, and general corporate purposes.
The sharp half-yearly jump in revenue and profits is positive for shareholders, suggesting strong operational momentum in H2 FY25, though full-year PAT was slightly lower year-on-year and EPS dipped. The clean auditor report and full deployment of IPO funds remove overhang concerns.